Echo Therapeutics (Echo Therapeutics) Interest Expense : $-0.29 Mil (TTM As of Sep. 2016)

View and export this data going back to 1997. Start your Free Trial

What is Echo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Echo Therapeutics's interest expense for the three months ended in Sep. 2016 was $ -0.13 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.29 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Echo Therapeutics's Operating Income for the three months ended in Sep. 2016 was $ -1.81 Mil. Echo Therapeutics's Interest Expense for the three months ended in Sep. 2016 was $ -0.13 Mil. Echo Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Echo Therapeutics Interest Expense Historical Data

The historical data trend for Echo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Echo Therapeutics Interest Expense Chart

Echo Therapeutics Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.51

-3.90

-0.02

Echo Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Interest Expense	Get a 7-Day Free Trial															-0.26	-0.01	-0.04	-0.11	-0.13

Echo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29 Mil.

Echo Therapeutics (OTCPK:ECTE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Echo Therapeutics's Interest Expense for the three months ended in Sep. 2016 was $-0.13 Mil. Its Operating Income for the three months ended in Sep. 2016 was $-1.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2016 was $0.00 Mil.

Echo Therapeutics's Interest Coverage for the quarter that ended in Sep. 2016 is calculated as

Echo Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Echo Therapeutics (Echo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Echo Therapeutics Inc (OTCPK:ECTE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Wood Avenue South, Suite 302, Iselin, NJ, USA, 08830

Website

http://www.echotx.com

Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable health consumer and the diabetes outpatient market.

Executives

Michael M Goldberg	director	C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Uri Landesman	10 percent owner	230 PARK AVENUE, NEW YORK NY 10169
Platinum Partners Value Arbitrage Fund, Lp	10 percent owner	250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019
Mark Nordlicht	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum Management (ny) Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Platinum-montaur Life Sciences, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Partners Liquid Opportunity Master Fund L.p.	10 percent owner	152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019
Platinum Liquid Opportunity Management (ny) Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355
Vincent D Enright	director	ONE CORPORATE CENTER, RYE NY 10580
William Grieco	director	830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Robert F Doman	director, officer: EXEC. CHAIRMAN AND INTERIM CEO	C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887
Patrick T Mooney	director, officer: CEO AND PRESIDENT	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Christopher P. Schnittker	officer: CFO	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540

Echo Therapeutics (Echo Therapeutics) Headlines

No Headlines